BioSpace News Archive

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.

Axcelead, Inc. today announced that Dr. Yoshinori Ikeura, President and CEO of Axcelead, Inc., will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 9:00 a.m. Pacific Time.

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 a.m. PT on Thursday, January 11, 2024 in San Francisco, CA.

RetinalGeniX Technologies Inc., announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, reported new data from the 12-month long-term open label extension of the CNM-Au8® treatment arm in the HEALEY ALS Platform Trial.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 a.m. PT.

Natera, Inc. today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA).

Cytek Biosciences, Inc., a leading cell analysis solutions company, announced the introduction of the Cytek Orion™ reagent cocktail preparation system.